Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83


Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261. [Epub ahead of print] Review.


Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.

Bhatia R, Serrano I, Wennington H, Graham C, Cubie H, Boland E, Fu G, Cuschieri K.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01687-17. doi: 10.1128/JCM.01687-17. Print 2018 Mar.


RNASeq analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus type 16 infection, including loss of epithelial barrier function.

Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, Pollock C, Bhatia R, Cuschieri K, Herzyk P, Gatherer D, Graham SV.

J Virol. 2017 Oct 11. pii: JVI.01001-17. doi: 10.1128/JVI.01001-17. [Epub ahead of print]


Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.

Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, Robertson C.

Lancet Infect Dis. 2017 Dec;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1. Epub 2017 Sep 28.


Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.

Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, Patterson L, Govan L, Black J, Palmer T, Arbyn M.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1629-1635. doi: 10.1158/1055-9965.EPI-17-0534. Epub 2017 Sep 8.


The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.

Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG.

J Epidemiol Community Health. 2017 Oct;71(10):954-960. doi: 10.1136/jech-2017-209113. Epub 2017 Jul 29.


The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.

Munro A, Gillespie C, Cotton S, Busby-Earle C, Kavanagh K, Cuschieri K, Cubie H, Robertson C, Smart L, Pollock K, Moore C, Palmer T, Cruickshank ME.

BJOG. 2017 Aug;124(9):1394-1401. doi: 10.1111/1471-0528.14563. Epub 2017 Mar 9.


Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.

Cruickshank ME, Pan J, Cotton SC, Kavanagh K, Robertson C, Cuschieri K, Cubie H, Palmer T, Pollock KG.

BJOG. 2017 Aug;124(9):1386-1393. doi: 10.1111/1471-0528.14562. Epub 2017 Mar 9.


HPV status and favourable outcome in vulvar squamous cancer.

Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, Burton K, Reed NS, Graham SV.

Int J Cancer. 2017 Mar 1;140(5):1134-1146. doi: 10.1002/ijc.30523.


Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings.

Conway DI, Robertson C, Gray H, Young L, McDaid LM, Winter AJ, Campbell C, Pan J, Kavanagh K, Kean S, Bhatia R, Cubie H, Clarkson JE, Bagg J, Pollock KG, Cuschieri K.

PLoS One. 2016 Nov 18;11(11):e0165847. doi: 10.1371/journal.pone.0165847. eCollection 2016.


HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology.

Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, Rapozo D, Long A, Cubie H, Junor E, Monaghan H, Harrington KJ, Nutting CM, Schick U, Lau AS, Upile N, Sheard J, Brougham K, West CM, Oguejiofor K, Thomas S, Ness AR, Pring M, Thomas GJ, King EV, McCance DJ, James JA, Moran M, Sloan P, Shaw RJ, Evans M, Jones TM.

Cancer Res. 2016 Nov 15;76(22):6598-6606. doi: 10.1158/0008-5472.CAN-16-0633. Epub 2016 Aug 28.


Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma.

Pattle SB, Utjesanovic N, Togo A, Wells L, Conn B, Monaghan H, Junor E, Johannessen I, Cuschieri K, Talbot S.

Genes Chromosomes Cancer. 2017 Mar;56(3):185-198. doi: 10.1002/gcc.22425. Epub 2016 Nov 21.


Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M.

J Clin Microbiol. 2016 Sep;54(9):2337-42. doi: 10.1128/JCM.00897-16. Epub 2016 Jul 6.


Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.

Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N.

Br J Cancer. 2016 Jul 12;115(2):212-22. doi: 10.1038/bjc.2016.199. Epub 2016 Jun 28.


Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.


Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.

Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M.

J Clin Virol. 2016 Aug;81:6-11. doi: 10.1016/j.jcv.2016.05.004. Epub 2016 May 19.


Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.

Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG.

Br J Cancer. 2016 May 24;114(11):1261-4. doi: 10.1038/bjc.2016.97. Epub 2016 Apr 26.


Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, Arbyn M.

BMJ Open. 2016 Apr 25;6(4):e010660. doi: 10.1136/bmjopen-2015-010660.


Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.

Moore C, Duvall E, Braby E, Reid G, Docherty E, Grieve L, Cubie H, Graham C, Cuschieri K.

J Clin Virol. 2016 Jun;79:32-35. doi: 10.1016/j.jcv.2016.03.020. Epub 2016 Mar 22.


HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Cotton S, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):582-9. doi: 10.1038/bjc.2015.474. Epub 2016 Feb 4.


Formalin fixed paraffin embedded (FFPE) material is amenable to HPV detection by the Xpert(®) HPV assay.

Guerendiain D, Moore C, Wells L, Conn B, Cuschieri K.

J Clin Virol. 2016 Apr;77:55-9. doi: 10.1016/j.jcv.2016.02.007. Epub 2016 Feb 11. Erratum in: J Clin Virol. 2016 Apr;77:116.


Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women.

Leonard SM, Pereira M, Roberts S, Cuschieri K, Nuovo G, Athavale R, Young L, Ganesan R, Woodman CB.

Sci Rep. 2016 Feb 15;6:20847. doi: 10.1038/srep20847.


Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.

Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, Pan J, Pollock KG, Palmer TJ, Cuschieri K.

Int J Cancer. 2016 Jun 15;138(12):2922-31. doi: 10.1002/ijc.30030. Epub 2016 Feb 26.


HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):576-81. doi: 10.1038/bjc.2015.473. Epub 2016 Jan 22.


Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.

Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KG.

Emerg Infect Dis. 2016 Jan;22(1):56-64. doi: 10.3201/eid2201.150736.


HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.

Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E.

J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28. doi: 10.1016/j.jcv.2015.10.025. Epub 2015 Nov 10. Review.


HPV testing in the context of post-treatment follow up (test of cure).

Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S56-S61. doi: 10.1016/j.jcv.2015.10.008. Epub 2015 Oct 22. Review.


VALGENT: A protocol for clinical validation of human papillomavirus assays.

Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W.

J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21. doi: 10.1016/j.jcv.2015.09.014. Epub 2015 Oct 8. Review.


The role of infection in miscarriage.

Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW.

Hum Reprod Update. 2016 Jan-Feb;22(1):116-33. doi: 10.1093/humupd/dmv041. Epub 2015 Sep 19. Review.


Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M.

J Clin Microbiol. 2015 Oct;53(10):3272-9. doi: 10.1128/JCM.01366-15. Epub 2015 Aug 5.


Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine.

Hanley SJ, Pollock KG, Cuschieri K.

Intern Med. 2015;54(15):1953. doi: 10.2169/internalmedicine.54.4479. Epub 2015 Aug 1. No abstract available.


Population-based p16 and HPV positivity rates in oropharyngeal cancer in Southeast Scotland.

Wells LA, Junor EJ, Conn B, Pattle S, Cuschieri K.

J Clin Pathol. 2015 Oct;68(10):849-52. doi: 10.1136/jclinpath-2015-202947. Epub 2015 Jul 7.


Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, Poljak M.

Clin Microbiol Infect. 2015 Sep;21(9):817-26. doi: 10.1016/j.cmi.2015.04.015. Epub 2015 May 1. Review.


Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment.

Stanczuk GA, Currie H, Baxter G, Foster A, Gibson L, Graham C, Cuschieri K.

J Clin Pathol. 2015 Jul;68(7):567-70. doi: 10.1136/jclinpath-2014-202851. Epub 2015 Apr 15.


Increased cycling cell numbers and stem cell associated proteins as potential biomarkers for high grade human papillomavirus+ve pre-neoplastic cervical disease.

Canham M, Charsou C, Stewart J, Moncur S, Hoodless L, Bhatia R, Cong D, Cubie H, Busby-Earle C, Williams A, McLoughlin V, Campbell JD, Cuschieri K, Howie S.

PLoS One. 2014 Dec 22;9(12):e115379. doi: 10.1371/journal.pone.0115379. eCollection 2014.


Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.

Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.

J Clin Pathol. 2015 Feb;68(2):135-40. doi: 10.1136/jclinpath-2014-202681. Epub 2014 Nov 19.


Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2014 Nov;52(11):3996-4002. doi: 10.1128/JCM.01962-14. Epub 2014 Sep 10. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1927.


Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.

Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M.

Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 10.1038/bjc.2014.479. Epub 2014 Sep 2.


An evaluation of the Qiagen HPV sign for the detection and genotyping of cervical lesions and oropharyngeal squamous cell carcinomas.

Ward C, Pedraza J, Kavanagh K, Johannessen I, Cuschieri K.

J Virol Methods. 2014 Oct;207:128-32. doi: 10.1016/j.jviromet.2014.07.001. Epub 2014 Jul 9.


Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer.

Cuschieri K, Brewster DH, Graham C, Nicoll S, Williams AR, Murray GI, Millan D, Johannessen I, Hardie A, Cubie HA.

Int J Cancer. 2014 Dec 1;135(11):2721-6. doi: 10.1002/ijc.28902. Epub 2014 Apr 29.


Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.

Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M.

Br J Cancer. 2014 May 27;110(11):2804-11. doi: 10.1038/bjc.2014.198. Epub 2014 Apr 15.


Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).

Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K.

J Clin Pathol. 2014 Jun;67(6):458-63. doi: 10.1136/jclinpath-2013-202014. Epub 2014 Jan 16.


Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.

Cuschieri K, Cubie H, Graham C, Rowan J, Hardie A, Horne A, Earle CB, Bailey A, Crosbie EJ, Kitchener H.

J Clin Virol. 2014 Feb;59(2):104-8. doi: 10.1016/j.jcv.2013.12.001. Epub 2013 Dec 12.


Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.

Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S.

Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029. Review.


Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact.

Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C.

BMC Infect Dis. 2013 Nov 5;13:519. doi: 10.1186/1471-2334-13-519.


Reply to triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Arbyn M, Verdoodt F, Cuschieri K.

Cancer Cytopathol. 2014 Jan;122(1):77-8. doi: 10.1002/cncy.21359. Epub 2013 Oct 29. No abstract available.


Assessing the detection of human papillomavirus late mRNA in liquid base cytology samples for risk stratification of cervical disease.

Chambers G, Millan D, Cuschieri K, Cubie HA, Graham SV.

J Med Virol. 2014 Apr;86(4):627-33. doi: 10.1002/jmv.23793. Epub 2013 Oct 19.


Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).

Powell N, Cuschieri K, Cubie H, Hibbitts S, Rosillon D, De Souza SC, Molijn A, Quint W, Holl K, Fiander A.

J Clin Virol. 2013 Nov;58(3):571-4. doi: 10.1016/j.jcv.2013.08.020. Epub 2013 Aug 30.


Understanding HPV tests and their appropriate applications.

Cubie HA, Cuschieri K.

Cytopathology. 2013 Oct;24(5):289-308. doi: 10.1111/cyt.12083. Epub 2013 Sep 2. Review.


Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review.

Supplemental Content

Loading ...
Support Center